Search

Lynne N Georgopoulos

from Collegeville, PA
Age ~61
Get Report
Also known as:
Lynne M Georgopoulos, Lynne E Georgopoulos, Lynne J Georgopoulos, Lynn Jojo Georgopoulos, Lynne M Georgepoulos, Lynne N Georgepoulos, Lynne M Jojo, Lynne S, Ly Georgopoulos, Lynn Georgeopoulos
Phone and address:
112 7Th Ave, Collegeville, PA 19426
(610) 489-2957
Related to:
Alexander Georgopoulos, 71Nikolas Georgopoulos, 31Alex Georgopoulos, 61
Connected to:
Anthony Georgopoulos, 75Katherine P Georgopoulos, 45Marianne D Georgopolos, 64Steven Georgopulos, 75Todd M Georgopapadakos, 54Chris S Georgoulias, 44Irene G Georgoulakos, 79James Georgoudes, 93Kathryn Georgoulis, 68Melissa M Georgoudis, 33

Lynne Georgopoulos Phones & Addresses

  • 112 7Th Ave, Collegeville, PA 19426 (610) 489-2957 (610) 489-6456
  • Lansdale, PA
  • Oxnard, CA
  • New Britain, CT
  • Troy, NY
  • 112 7Th Ave, Collegeville, PA 19426 (610) 489-6456

Work

Company: Certara Apr 2020 Position: Vice president regulatory strategy

Education

Degree: Master of Science, Masters School / High School: The George Washington University 2015 to 2016

Skills

Clinical Development • Clinical Trials • Regulatory Affairs • Fda • Clinical Research • Gcp • Drug Development • Biotechnology • Clinical Operations • Medical Writing • Ich Gcp • Clinical Monitoring • Pharmaceutical Industry • Regulatory Submissions • Clinical Data Management • Registered Nurses • Nursing • Therapeutic Areas • Infectious Diseases • U.s. Food and Drug Administration • Good Clinical Practice • Cardiology

Industries

Pharmaceuticals

Resumes

Resumes

Lynne Georgopoulos Photo 1

Vice President Regulatory Strategy

View page
Location:
4020 Aerial Center Pkwy, Morrisville, NC 27560
Industry:
Pharmaceuticals
Work:
Certara
Vice President Regulatory Strategy
Synteracthcr
Vice President Pediatric Development, Americas
Kinderpharm Llc
Senior Vice President Clinical Development and Regulatory Affairs
Phasebio Pharmaceuticals, Inc. Feb 2010 - Apr 2016
Senior Vice President Clinical Development
Phasebio Pharmaceuticals, Inc. Feb 2010 - Oct 2010
Vice President Clinical Operations and Regulatory Affairs
Education:
The George Washington University 2015 - 2016
Master of Science, Masters Russell Sage College 1981 - 1985
Bachelors, Bachelor of Science, Nursing
Skills:
Clinical Development
Clinical Trials
Regulatory Affairs
Fda
Clinical Research
Gcp
Drug Development
Biotechnology
Clinical Operations
Medical Writing
Ich Gcp
Clinical Monitoring
Pharmaceutical Industry
Regulatory Submissions
Clinical Data Management
Registered Nurses
Nursing
Therapeutic Areas
Infectious Diseases
U.s. Food and Drug Administration
Good Clinical Practice
Cardiology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Lynne Georgopoulos
Executive Vice-President
PhaseBio Pharmaceuticals
Biotechnology · Commercial Physical Research
1 Great Vly Pkwy SUITE 30, Malvern, PA 19355
(610) 981-6500

Publications

Us Patents

Methods Of Treatment With Glp-1 Receptor Agonists

View page
US Patent:
20130090285, Apr 11, 2013
Filed:
Jun 27, 2012
Appl. No.:
13/534836
Inventors:
Lynne M. Georgopoulos - Malvern PA, US
Susan Arnold - Malvern PA, US
Assignee:
PHASEBIO PHARMACEUTICALS, INC. - MALVERM PA
International Classification:
A61K 38/39
A61K 38/26
US Classification:
514 53
Abstract:
The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.

Formulations Of Active Agents For Sustained Release

View page
US Patent:
20170136092, May 18, 2017
Filed:
Nov 18, 2016
Appl. No.:
15/355386
Inventors:
- Malvern PA, US
Christopher PRIOR - Malvern PA, US
Lynne GEORGOPOULOS - Malvern PA, US
International Classification:
A61K 38/22
A61K 9/00
A61K 38/16
Abstract:
The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.

Formulations Of Active Agents For Sustained Release

View page
US Patent:
20150290328, Oct 15, 2015
Filed:
Nov 20, 2013
Appl. No.:
14/646273
Inventors:
- Melvern PA, US
Christopher Prior - Malvern PA, US
Lynne Georgopoulos - Malvern PA, US
International Classification:
A61K 47/42
A61K 38/26
A61K 45/06
A61K 38/22
A61K 47/48
A61K 47/02
A61K 9/00
A61K 47/18
A61K 38/28
Abstract:
The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.

Use Of Modified Vasoactive Intestinal Peptides In The Treatment Of Hypertension

View page
US Patent:
20150111829, Apr 23, 2015
Filed:
Jun 6, 2012
Appl. No.:
14/124612
Inventors:
Lynne M. Georgopoulos - Malvern PA, US
Susan Arnold - Malvern PA, US
Assignee:
PHASEBIO PHARMACEUTICALS, INC. - Malvern PA
International Classification:
A61K 38/39
A61K 31/4418
A61K 31/4045
A61K 31/165
US Classification:
514 157
Abstract:
The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.
Control profile
Lynne N Georgopoulos from Collegeville, PA, age ~61 Get Report